Real-world overall survival in advanced melanoma from the IMAGE study.

9531Background: IMAGE (ipilimumab: management of advanced melanoma in real practice) is an ongoing multinational, prospective, observational study that assesses the treatment of advanced (unresectable or metastatic) melanoma (MEL) in a real-world setting. Although there are adequate accumulating overall survival (OS) data from randomized controlled trials for patients (pts) diagnosed with advanced MEL, OS data from robust real-world studies are not available. As a result, the IMAGE study evaluated OS in pts with advanced MEL who received ipilimumab (IPI) and non-IPI therapies. Methods: IMAGE included adult pts who were not participating in a clinical trial and received IPI or other non-IPI therapies. Pts were followed from study enrollment (April 2012) to data extraction (November 27, 2015). Data were collected by electronic case report forms. Results: Of the 1,371 pts included in this study, 84% (n = 1,152) received IPI therapy and 16% (n = 219) did not receive IPI at any time during the study period. At...